Skip to main content

Rhode Island Department of Health Leverages SurveyMonkey Enterprise for Agile COVID-19 Tracking System

SAN MATEO, Calif., May 04, 2020 (GLOBE NEWSWIRE) — SurveyMonkey (Nasdaq: SVMK) today announced that the Rhode Island Department of Health (RIDOH) has deployed SurveyMonkey’s Enterprise Solution and Salesforce Integration in approximately 11 days to assist in COVID-19 tracking efforts. Through its HIPAA-compliant survey offering, SurveyMonkey enables the RIDOH to monitor all individuals exposed to the coronavirus who opt-in through daily survey links sent via SMS text. The data will help the RIDOH to track and monitor the virus’ impact.
“The name of the game here is data. Over time it will be vital for us to have regularly updated information statewide on COVID-19,” said Governor of Rhode Island, Gina Raimondo during a recent press conference addressing these efforts. “That data is going to be gold for us as we manage this crisis—especially after the economy reopens—so we can better understand it.”Integrating directly into Salesforce workflows and processes, SurveyMonkey Enterprise enables the RIDOH to simplify data collection while syncing real-time feedback of those who elect to be traced. This provides the RIDOH with a robust system allowing them to automate survey distribution, follow-up actions and reporting. The RIDOH then has direct access to the aggregate data to better understand the disease and eventually predict if the virus is going to hit a particular area or population.As part of the RIDOH’s comprehensive efforts around contract tracing and keeping the state’s population safe, the survey also enables the RIDOH to track symptoms and duration, gauge constituents’ access to essential services, and automatically direct individuals to the resources that are available through survey logic. The program is voluntary and opt-in for residents.SurveyMonkey Enterprise integrates with over 100 systems of record and secures confidential data with single sign-on (SSO), data encryption and access controls while offering security features that support customer compliance with data regulations such as HIPAA and the GDPR.“Real-time data collection is critical during a crisis that is rapidly evolving on a daily basis. We cannot afford to fall behind and need to arm government officials and healthcare professionals with premium insights that drive the decisions that will aid in controlling the pandemic,” said Tom Hale, president at SurveyMonkey. “The team at SurveyMonkey is proud to act as a strategic partner in this process to give leaders the necessary data to take swift and meaningful action.”For more information on how SurveyMonkey can support government agencies through the coronavirus crisis with scalable, customizable solutions and professional services to help meet urgent data needs, please contact gov@surveymonkey.com.SurveyMonkey has made additional efforts to help combat the pandemic including a recent collaboration with COVID Near You to collect diverse data sets across the U.S. to better understand the rapid changes and growth of the virus to improve aid. SurveyMonkey is also providing real-time data, employee engagement survey templates and other resources which can be found here.About SurveyMonkey
SurveyMonkey is a leading global survey software company on a mission to power the curious. The company’s platform empowers over 17 million active users to measure and understand feedback from employees, customers, website and app users, and the market. SurveyMonkey’s products, enterprise solutions and integrations enable more than 335,000 organizations to solve daily challenges, from delivering better customer experiences to increasing employee retention. With SurveyMonkey, organizations around the world can transform feedback into business intelligence that drives growth and innovation.
Media contact
Sandra Gharib
sandrag@surveymonkey.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.